June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Short term efficacy and safety of intravitreal preservative-free triamcinolone acetonide for the treatment of macular edema
Author Affiliations & Notes
  • Piero Fontana
    Ophthalmology, ASST Bergamo EST, Seriate, Bergamo, Italy
  • Antonio Fusca
    Ophthalmology, ASST Bergamo EST, Seriate, Bergamo, Italy
  • Serena Zanchi
    Ophthalmology, Clinica Castelli, Bergamo, Italy
  • Footnotes
    Commercial Relationships   Piero Fontana, None; Antonio Fusca, None; Serena Zanchi, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3694. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Piero Fontana, Antonio Fusca, Serena Zanchi; Short term efficacy and safety of intravitreal preservative-free triamcinolone acetonide for the treatment of macular edema. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3694.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : to investigate short term efficacy and safety of intravitreal preservative-free triamcinolone acetonide (IVTA) for the treatment of macular edema in different ocular pathologies. This is a retrospective, observational clinical study to learn about ocular effects after IVTA as first intravitreal therapy

Methods : 126 eyes of 126 patients (mean age: 71.23 ± 18.23 years) with diabetic macular edema (DME), branch retinal vein occlusion (BRVO) and pseudophakic macular edema (PME) were treated with a single 4mg/0.1 ml IVTA injection and completed a four months follow-up.
Outcomes measures were: central macular thickness (CMT), best corrected visual acuity (BCVA), intraocular pressure (IOP) increase and cataract progression.

Results : 16 weeks after the IVTA injection, average CMT decreased from baseline 531.31 ± 239.31 µm to 307.26 ± 167.62 µm. Mean decimal BCVA increased from baseline 0.19 ± 0.18 to 0.38 ± 0.33.
During the entire follow-up period IOP values over 21 mmHg were measured in 41 (32.5%) patients. In all cases IOP was controlled with topical treatment only.
Significant intraocular inflammation did not develop in any patient.
Cataract progression was found in 18 (21.4%) of the 84 phakic patients

Conclusions : preservative-free IVTA was effective and relatively safe in the treatment of different groups of macular edema with good temporary beneficial effect on CMT and BCVA

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×